574 related articles for article (PubMed ID: 9508381)
1. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.
Reali UM; Martini L; Borgognoni L; Semino C; Pietra G; Chiarugi C; Guastella M; Melioli G
Melanoma Res; 1998 Feb; 8(1):77-82. PubMed ID: 9508381
[TBL] [Abstract][Full Text] [Related]
2. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
3. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
5. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.
Mihm MC; Clemente CG; Cascinelli N
Lab Invest; 1996 Jan; 74(1):43-7. PubMed ID: 8569196
[TBL] [Abstract][Full Text] [Related]
6. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis after sentinel node biopsy in malignant melanoma].
Lock-Andersen J; Horn J; Sjøstrand H
Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
[TBL] [Abstract][Full Text] [Related]
9. Vulvar melanoma: is there a role for sentinel lymph node biopsy?
de Hullu JA; Hollema H; Hoekstra HJ; Piers DA; Mourits MJ; Aalders JG; van der Zee AG
Cancer; 2002 Jan; 94(2):486-91. PubMed ID: 11905414
[TBL] [Abstract][Full Text] [Related]
10. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
12. [Surgical technique and postoperative morbidity following radical inguinal/iliacal lymph node dissection--a prospective study in 67 patients with malignant melanoma metastatic to the groin].
Mall JW; Reetz C; Koplin G; Schäfer-Hesterberg G; Voit C; Neuss H
Zentralbl Chir; 2009 Sep; 134(5):437-42. PubMed ID: 19757344
[TBL] [Abstract][Full Text] [Related]
13. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
14. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
15. Combined-modality therapy for patients with regional nodal metastases from melanoma.
Ballo MT; Ross MI; Cormier JN; Myers JN; Lee JE; Gershenwald JE; Hwu P; Zagars GK
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):106-13. PubMed ID: 16182463
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
[TBL] [Abstract][Full Text] [Related]
18. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
Fisher SR
Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
[TBL] [Abstract][Full Text] [Related]
19. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
[TBL] [Abstract][Full Text] [Related]
20. Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin.
Allan CP; Hayes AJ; Thomas JM
ANZ J Surg; 2008 Nov; 78(11):982-6. PubMed ID: 18959697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
